Screening a plant extract library for inhibitors of cholecystokinin receptor CCK1 pathways

Journal of Biomolecular Screening

Volumn 15, Issue 5, 2010, Pages 518-527

  Nesterov, Alexandre ^a   Mei Hong, ^a   Hertel, Carmen ^a   Ping Jiao, ^a   Brownell, Lidia ^a   Cannon, Edward ^a  

^a Unigen Pharmaceuticals Inc   (United States)

Author keywords

lactamase gene reporter; Cholecystokinin receptor CCK1; G q 11 selective inhibitor; Plant extract library; Screening

Indexed keywords

ARDISIA CRENATA EXTRACT; BETA LACTAMASE; CALCIUM ION; CCK1; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; LORGLUMIDE; UNCLASSIFIED DRUG;

ARDISIA; ARDISIA CRENATA; ARTICLE; DRUG PROTEIN BINDING; DRUG SCREENING; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ARDISIA; BIOLOGICAL ASSAY; CELL LINE; CHOLECYSTOKININ; GENES, REPORTER; PLANT EXTRACTS; PLANT PROTEINS; RECEPTORS, CHOLECYSTOKININ; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 77953623547     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110369702     Document Type: Article

References (18)

1. Harvey AL: Natural products in drug discovery. Drug Discov Today 2008 ; 13: 894-901.
2. Li JW, Vederas JC: Drug discovery and natural products: end of an era or an endless frontier ? Science 2009 ; 325: 161-165.
3. Jia Q.: Generating and screening a natural product library for cyclooxygenase and lipoxygenase dual inhibitors. Studies Natural Prod Chem 2002 ; 29: 643-718.
4. Vu H., Pham NB, Quinn RJ: Direct screening of natural product extracts using mass spectrometry. J Biomol Screen 2008 ; 13: 265-275.
5. Sasiela CA, Stewart DH, Kitagaki J., Safiran YJ, Yang Y., Weissman AM,, et al. Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen. J Biomol Screen 2008 ; 13: 229-237.
6. Noble F., Wank SA, Crawley JN, Bradwejn J., Seroogy KB, Hamon M.,, et al. International Union of Pharmacology: XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999 ; 51: 745-781.
7. Herranz R.: Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 2003 ; 23: 559-605.
8. Zlokarnik G., Negulescu PA, Knapp TE, Mere L., Burres N., Feng L.,, et al. Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 1998 ; 279: 84-88.
9. Kunapuli P., Ransom R., Murphy KL, Pettibone D., Kerby J., Grimwood S.,, et al. Development of an intact cell reporter gene beta-lactamase assay for G protein-coupled receptors for high-throughput screening. Anal Biochem 2003 ; 314: 16-29.
10. Oosterom J., van Doornmalen EJ, Lobregt S., Blomenrohr M., Zaman GJ: High-throughput screening using beta-lactamase reporter-gene technology for identification of low-molecular-weight antagonists of the human gonadotropin releasing hormone receptor. Assay Drug Dev Technol 2005 ; 3: 143-154.
11. Makovec F., Bani M., Cereda R., Chiste R., Pacini MA, Revel L.,, et al. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung 1987 ; 37: 1265-1268.
12. Takasaki J., Saito T., Taniguchi M., Kawasaki T., Moritani Y., Hayashi K.,, et al. A novel Galphaq/11-selective inhibitor. J Biol Chem 2004 ; 279: 47438-47445.
13. McDonald IM, Black JW, Buck IM, Dunstone DJ, Griffin EP, Harper EA,, et al. Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion. J Med Chem 2007 ; 50: 3101-3112.
14. Gomez L., Hack MD, McClure K., Sehon C., Huang L., Morton M.,, et al. SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists. Bioorg Med Chem Lett 2007 ; 17: 6493-6498.
15. Fujioka M., Koda S., Morimoto Y.: Structure of FR900359, a cyclic depsipeptide from Ardisia crenata sims. J Org Chem 1988 ; 53: 2820-2825.
16. Uemura T., Kawasaki T., Taniguchi M., Moritani Y., Hayashi K., Saito T.,, et al. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress. Br J Pharmacol 2006 ; 148: 61-69.
17. Uemura T., Takamatsu H., Kawasaki T., Taniguchi M., Yamamoto E., Tomura Y.,, et al. Effect of YM-254890, a specific Galphaq/11 inhibitor, on experimental peripheral arterial disease in rats. Eur J Pharmacol 2006 ; 536: 154-161.
18. Kawasaki T., Taniguchi M., Moritani Y., Uemura T., Shigenaga T., Takamatsu H.,, et al. Pharmacological properties of YM-254890, a specific G(alpha) q/11 inhibitor, on thrombosis and neointima formation in mice. Thromb Haemost 2005 ; 94: 184-192.